Friday, August 1, 2014

Clinical trials of anti-malarial vaccines

"This study" provides a number of new vaccine candidates that offer real hope "-  Dr. Faith Osier,  Medical Research Institute of Kenya (KEMRI)

Malaria is responsible for over 600,000 deaths per year worldwide, mostly young children in sub-Saharan Africa.

Complete protection against malaria?

Researchers followed for more than six months a carrying malaria parasites group of children. Some have developed the disease, while others have been protected by natural antibodies have impeded their parasites to penetrate blood cells and their spared severe symptoms (fever, anemia).

Blood samples from these have helped to identify combinations of antibodies can confer complete protection against malaria, said the researchers.

Clinical trials of anti-malarial vaccines in the past focused on a single target and had limited success, "said Dr. Julian Rayner, the Sanger Institute in the UK, one of the authors of the study.

"With this approach, we can systematically test a greater number of targets as well as combinations of targets," he says.

The Anopheles mosquito is a major vector of malaria in the world. Apart from the growing resistance to antimalarial drugs, mosquitoes are less affected by insecticides. This phenomenon makes it all the more important search for new vaccine solutions.

No comments:

Post a Comment